Emerson Keenan

Emerson Keenan
University of Melbourne | MSD · Department of Electrical and Electronic Engineering and Department of Obstetrics and Gynaecology

PhD

About

25
Publications
2,149
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
38
Citations
Introduction
Emerson Keenan is a Research Fellow working in the Department of Obstetrics and Gynaecology at The University of Melbourne. His research interests include biomedical signal processing and machine learning, with a specific focus on developing technology for pregnancy monitoring.

Publications

Publications (25)
Article
Objective: Non-invasive fetal electrocardiography (NI-FECG) shows promise for capturing novel physiological information that may indicate signs of fetal distress. However, significant deterioration in NI-FECG signal quality occurs during the presence of a highly non-conductive layer known as vernix caseosa which forms on the fetal body surface beg...
Conference Paper
Full-text available
With the introduction of wearable sensors and the Internet of Things (IoT), the use of physiological signals to continuously assess our mental and physical state is growing rapidly. This field offers an exciting opportunity for students to develop a range of science, technology, engineering and mathematics (STEM) skills using widely available low-c...
Article
Preeclampsia complicates 5–8% of all pregnancies and is associated with high rates of maternal and perinatal morbidity. The majority of cases occur at term gestations where the baby can be safely delivered. The preeclampsia disease process however can progress in the mother resulting in significant morbidity. In this study we were interested in exa...
Article
Fetal cardiac monitoring is one of the cornerstones of modern obstetric care. Noninvasive fetal electrocardiography (NI-FECG) is an emerging modality for monitoring fetal well-being using electrical signals recorded from the maternal abdomen. However, the reliability of NI-FECG extraction techniques remains highly variable due to a range of technic...
Article
Objective: Fetal arrhythmias are a life-threatening disorder occurring in up to 2% of pregnancies. If identified, many fetal arrhythmias can be effectively treated using anti-arrhythmic therapies. In this paper, we present a novel method of detecting fetal arrhythmias in short length non-invasive fetal electrocardiography (NI-FECG) recordings. Appr...
Article
Full-text available
Preeclampsia is a devastating, multisystem disorder of pregnancy. It has no cure except delivery, which if premature can impart significant neonatal morbidity. Efforts to repurpose pregnancy-safe therapeutics for the treatment of preeclampsia have led to the assessment of the proton pump inhibitor, esomeprazole. Preclinically, esomeprazole reduced...
Article
Full-text available
Background Preeclampsia is pregnancy specific, involving significant maternal endothelial dysfunction. Predictive biomarkers are lacking. We evaluated the biomarker potential, expression, and function of PSG7 (pregnancy‐specific β‐1 glycoprotein 7) and PSG9 (pregnancy‐specific β‐1 glycoprotein 9) in preeclampsia. Methods and Results At 36 weeks ges...
Article
OBJECTIVE Serine peptidase inhibitor Kunitz- type-1 (SPINT1) is a circulating protein with possibly the strongest association with low birthweight and placental insufficiency yet reported. At 36 weeks’ gestation low plasma SPINT1 was strongly linked with birth of a neonate <10th centile birthweight (p=2.7 × 10⁻¹³; Australian cohort¹) as were levels...
Article
Full-text available
Fetal growth restriction (FGR), when undetected antenatally, is the biggest risk factor for preventable stillbirth. Maternal circulating SPINT1 is reduced in pregnancies, which ultimately deliver small for gestational age (SGA) infants at term (birthweight < 10th centile), compared to appropriate for gestational age (AGA) infants (birthweight ≥ 10t...
Article
First trimester circulating ADAM12 is reduced in fetal growth restriction (FGR) and preeclampsia. We measured plasma ADAM12 at 36 weeks’ gestation preceding diagnosis of term preeclampsia or delivery of a small for gestational age (SGA; birthweight <10th centile) infant in two independent cohorts (Cohort 1 90 SGA, 41 preeclampsia, 862 controls; Coh...
Article
Activin A is aberrantly expressed by the preeclamptic placenta and circulating levels have been investigated as a potential biomarker for the disease. In a nested cased-control study we measured Activin A levels in maternal plasma at 28- and 36-weeks’ gestation preceding term preeclampsia diagnosis. At 28 weeks Activin A was not significantly alter...
Conference Paper
Non-invasive fetal electrocardiography (NI-FECG) is an emerging tool with novel diagnostic potential for monitoring fetal wellbeing using electrical signals acquired from the maternal abdomen. However, variations in the geometric structure and conductivity of maternal-fetal tissues have been shown to affect the reliability of NI-FECG signals. Previ...
Article
Aim To assess the growth trajectory of preterm small-for-gestational-age (SGA) neonates compared to preterm non-small-for-gestational age neonates in the neonatal intensive care unit and special care nursery. Methods We conducted a retrospective cohort study at a large tertiary hospital in Victoria, Australia, examining neonates ≤34 weeks’ gestati...
Article
Full-text available
Fetal growth restriction is a leading cause of stillbirth that often remains undetected during pregnancy. Identifying novel biomarkers may improve detection of pregnancies at risk. This study aimed to assess syndecan-1 as a biomarker for small for gestational age (SGA) or fetal growth restricted (FGR) pregnancies and determine its molecular regulat...
Article
Full-text available
Background We investigated the biomarker potential of growth differentiation factor 15 (GDF‐15), a stress response protein highly expressed in placenta, to predict preeclampsia. Methods and Results In 2 prospective cohorts (cohort 1: 960 controls, 39 women who developed preeclampsia; cohort 2: 950 controls, 41 developed preeclampsia), plasma conce...
Article
Full-text available
Biomarkers for placental dysfunction are currently lacking. We recently identified SPINT1 as a novel biomarker; SPINT2 is a functionally related placental protease inhibitor. This study aimed to characterise SPINT2 expression in placental insufficiency. Circulating SPINT2 was assessed in three prospective cohorts, collected at the following: (1) te...
Article
Preeclampsia is a serious pregnancy complication associated with elevated antiangiogenic markers and endothelial dysfunction. Recently nicotinamide (vitamin B3) was shown to reduce high blood pressure and proteinuria in mice models of the disease. Using primary human pregnancy tissue we show nicotinamide did not change antiangiogenic factor secreti...
Article
Objective To investigate delivery indications for women with late preterm preeclampsia and evaluate whether disease characteristics at presentation are predictive of delivery indication. Methods We conducted a retrospective case-control study at the Mercy Hospital for Women (a tertiary hospital in Melbourne, Australia). Indication for delivery was...
Article
Introduction Tissue Factor Pathway Inhibitor (TFPI) is a part of the extrinsic coagulation pathway, and highly expressed in the placenta. We aimed to assess its potential as a preeclampsia biomarker. Methods Maternal plasma was prospectively collected at 36 weeks’ gestation. Circulating TFPI was measured in a nested case-control group (39 women wh...
Conference Paper
The use of fetal heart rate (FHR) recordings for assessing fetal wellbeing is an integral component of obstetric care. Recently, non-invasive fetal electrocardiography (NI-FECG) has demonstrated utility for accurately diagnosing fetal arrhythmias via clinician interpretation. In this work, we introduce the use of data-driven entropy profiling to au...
Conference Paper
Non-invasive fetal electrocardiography (NI-FECG) is an emerging technology that demonstrates potential for providing novel physiological information compared to traditional ultrasound-based cardiotocography (CTG). However, few studies have investigated the reliability of signal features derived via this technique for diagnostic use. One feature of...

Network

Cited By